Gilead (GILD 2.28%) will be reporting 4Q earnings on Monday, as well as the company's full 2012 results. In this video, Motley Fool health-care analyst David Williamson tells us why it has been a transformational year for the company, and what key things to watch for in the upcoming earnings report.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Foolish Preview: Gilead Earnings
By Dave Williamson
–
Jan 31, 2013 at 5:51PM
NASDAQ: GILD
Gilead Sciences
Market Cap
$139B
Today's Change
(2.28%) $2.50
Current Price
$112.14
Price as of July 14, 2025, 3:58 p.m. ET
A look ahead at what we can expect from Gilead.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Gilead Sciences
GILD
$112.14
(2.28%)
$2.50
Johnson & Johnson
JNJ
$156.91
(0.01%)
$0.01
AbbVie
ABBV
$191.52
(-0.48%)
$0.93
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Gilead Sciences: A Mixed Bag of Opportunities and Risks
Why Gilead Sciences Stock Tumbled on Tuesday
Why Gilead Sciences Stock Slipped Today
Why Gilead Sciences Stock Is Jumping Today
Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.